Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today
announced that Dr. Andrew Brenner, development leader of an
innovative drug portfolio platform that the company has recently
licensed, is scheduled to conduct a live patient-focused webinar
entitled, "A Promising New Radiotherapy for Recurrent Glioblastoma:
An Introduction", on Sunday, May 17, 2020, at 7 pm EDT.
The event, part of the Musella Foundation Webinar Series, is to
be presented live on the Foundation’s website at
virtualtrials.com/webinar/ through a Zoom room. If there is
overflow, the webinar may also be streamed live on Facebook at
facebook.com/Braintumor. Participants are asked to join the
digital room 5 minutes before the event and may ask questions live
or email questions in advance to musella@virtualtrials.com.
There is no charge for the event, although the Foundation welcomes
donations.
Plus Therapeutics is participating in the presentation as part
of its recognition of Brain Tumor Awareness Month. Every May,
a number of events and activities take place across the nation to
raise awareness of the fight against brain tumors.
On March 30, 2020, Plus Therapeutics announced that it had
entered into a definitive agreement to license the radiolabeled
nanoliposome drug portfolio platform developed by a
multi-institutional consortium based in Texas at the Mays Cancer
Center / UT Health San Antonio MD Anderson Cancer Center led by Dr.
Andrew Brenner, MD, PhD. Dr. Brenner is the Kolitz Chair in
Neuro-Oncology Research and Co-Leader of the Experimental and
Developmental Therapeutics Program.
The platform is anchored around nanoliposome-encapsulated
radionuclides for several cancer targets. The lead drug asset is a
chelated Rhenium NanoLiposome (RNL™), initially being developed for
recurrent glioblastoma. RNL™ is infused directly into the
brain tumor via precision brain mapping and convection enhanced
delivery technology to deliver very high therapeutic doses of
radiation to patients whose cancer has recurred following initial
surgical resection and treatment with chemotherapy and
radiation.
The licensed technology was previously funded by both the
National Institutes of Health/National Cancer Institute (NIH/NCI)
and the Cancer Prevention and Research Institute of Texas
(CPRIT). There is an active $3.7 million award from NIH/NCI,
which will financially support the continued clinical development
of RNL™ for recurrent glioblastoma.
About Andrew Brenner, MD PhD
Dr. Brenner is a medical oncologist and tumor biologist with an
interest in drug development for the management of primary brain
tumors and breast neoplasms. At the basic research level, his
interests are in developing novel therapeutics for
the treatment of malignancy with a focus on overcoming
resistance to conventional therapeutics. This experience
includes navigation of regulatory processes including IND enabling
studies, authoring study protocols, coordinating multicenter
studies, as well as acting as principal investigator of 14
industry and investigator initiated phase 1 trials since 2008.
A graduate of Texas A&M University, Dr. Brenner earned his
bachelor’s degree in biochemistry and went on to earn his doctorate
in biological science and tumor biology at The University of Texas
M.D. Anderson Cancer Center - Science Park. Dr. Brenner received
his medical degree from the Texas Tech University Health
Science Center and completed a residency in internal medicine
at Scott and White Hospital in Lubbock, Texas. He completed
his fellowship in hematology and medical oncology at the UT Health
San Antonio.
About The Musella Foundation For Brain Tumor Research
& Information
The Musella Foundation is a
501(c)(3) nonprofit public charity dedicated to
helping brain tumor patients
through emotional and financial support, education, advocacy and
raising money for brain tumor research. Based in
Hewlett, N.Y., the foundation was founded by Dr. Al Musella, DPM, a
podiatrist in private practice in Hewlett. The foundation has
awarded over $4.7 million in direct patient assistance to help
patients receive treatment. More information may be found at
www.virtualtrials.com.
About Plus Therapeutics, Inc.
Plus Therapeutics is a clinical-stage pharmaceutical company
focused on making a positive impact on patients’ lives and adding
value to the healthcare system. We are a publicly-traded company on
Nasdaq (PSTV, an abbreviation of ‘POSITIVE’) with our headquarters
in Austin, Texas and GMP-validated manufacturing facilities in San
Antonio, Texas. The location of our operations provides us
with many potential strategic advantages, including proximity to
world-class cancer institutions and researchers and the ability to
qualify and apply for funding through the Cancer Prevention and
Research Institute of Texas, or CPRIT.
We have two lead drug product candidates in our pipeline, RNL™
and DocePLUS™, being developed in the U.S. by a dedicated and
energetic team of biologists, chemists, engineers, physicians, and
other professionals. This diverse and experienced team is
using our proprietary and versatile nanotechnology platform to
reformulate and deliver approved chemotherapeutics and widely-used
radiotherapeutics to provide meaningful benefits to patients and
healthcare providers. The platform also serves as the foundation
for the company’s drug development programs and affords us the
opportunity in the future to develop additional drugs for rare
cancers. More information may be found
at www.plustherapeutics.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains certain statements that may be
deemed “forward-looking statements” within the meaning of U.S.
securities laws. All statements, other than statements of
historical fact, that address activities, events or developments
that we intend, expect, project, believe or anticipate and similar
expressions or future conditional verbs such as will, should,
would, could or may occur in the future are forward-looking
statements. Such statements are based upon certain assumptions and
assessments made by our management in light of their experience and
their perception of historical trends, current conditions, expected
future developments and other factors they believe to be
appropriate. These statements include, without limitation,
statements about: the Company’s potential to facilitate new
delivery approaches and/or formulations of safe and effective,
injectable drugs, potentially enhancing the safety, efficacy and
convenience for patients and healthcare providers; the Company’s
potential to develop drug candidates currently in its product
pipeline; and the Company’s potential to develop additional drugs
outside of its current pipeline. The forward-looking statements
included in this press release are subject to a number of
additional material risks and uncertainties, including but not
limited to: the risk that the Company is not able to successfully
develop product candidates that can leverage the U.S. FDA’s
accelerated regulatory pathways; and the risks described under the
heading “Risk Factors” in the Company’s Securities and Exchange
Commission filings, including in the Company’s annual and quarterly
reports. There may be events in the future that the Company is
unable to predict, or over which it has no control, and its
business, financial condition, results of operations and prospects
may change in the future. The Company assumes no responsibility to
update or revise any forward-looking statements to reflect events,
trends or circumstances after the date they are made unless the
Company has an obligation under U.S. federal securities laws to do
so.
Plus Therapeutics, Inc. Andrew Sims VP –
Marketing, Chief Financial Officer, Investor Relations Phone:
+1.619.333.4150 Email: ir@plustherapeutics.com
Website: plustherapeutics.com
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Apr 2024 to May 2024
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From May 2023 to May 2024